Executive Management Team

Peter Mørch Eriksen

CEO

Peter Mørch Eriksen was appointed CEO effective January 9, 2024. Mr. Eriksen served as CEO of BioPorto from 2013 – 2021. He has spent more than 20 years in the MedTech/life science industries, including as CEO of Sense A/S and VP of Medtronic. From these positions, Mr. Eriksen has extensive experience in creating growth, restructuring and funding in technology-intensive and complex companies. He is an experienced leader with a record of business within the medical device industry and has broad experience selling and developing medical devices for both small and large MedTech companies. He has an accounting background, supplemented with management experience.

Other directorships: FluoGuide A/S (Chair), Monsenso A/S (Chair), Pharma Equity Group A/S (Chair), MyBlueLabel Compliance Services ApS (Chair), PME Holding ApS.

Jeffrey N. Haas

US President & CEO

Jeffrey N. Haas joined as President & Chief Executive Officer of BioPorto Inc. in May 2024. Previously, he served as Corporate Officer and President of Infectious Disease Development Markets – Rapid Diagnostics at Abbott Laboratories, a global healthcare company based in Chicago, IL, and traded on the NYSE. Prior to this role, he held a number of leadership roles at AbbVie, the pharmaceutical business of Abbott that was spun off in 2013, and at Abbott prior to AbbVie’s establishment. Jeffrey holds a BS in Biology from Indiana University – Bloomington.

Gry Husby Larsen

EVP and Chief Legal Officer

Gry Husby Larsen was appointed Executive Vice President and Chief Legal Officer in April 2024. Prior to joining BioPorto, she was an Attorney-at-law at Knop & Co. Law Firm. Serving as BioPorto’s General Counsel since 2011, Gry leads the Company’s legal activities including compliance, fundraising, IPR, contracts, HR and ESG. From 2019 to 2024, she acted as external General Counsel for BioPorto while also serving as part-time General Counsel for FluoGuide A/S, Algiecel A/S and Unibio A/S. Her extensive legal and commercial experience in the biotech industry will be an important asset in growing and developing our business. Gry holds a Master of Law from University of Copenhagen.

Other directorships: Chairperson, BioPorto Diagnostics A/S

Nis Kruse

EVP, Strategic Partnerships and General Manager, EMEA & APAC

Nis Kruse was appointed Executive Vice President of Strategic Partnerships and General Manager of EMEA & APAC in December 2022. Most recently, Nis served as SVP & Chief Commercial Officer at SSI Diagnostica A/S, an in vitro diagnostics company focusing on infectious diseases, where he delivered substantial topline growth during the COVID pandemic. Previously, operating in a US-based position, Nis was Executive Director of Global Precision Medicine at Merck & Co. responsible for commercial diagnostic strategy and commercial partner management related to Keytruda®. Earlier in his career, he held leadership roles in Copenhagen at Agilent Technologies, H. Lundbeck, and AstraZeneca. Nis holds Master’s and Bachelor’s degrees in Economics and Business Management from Aarhus University (Denmark).

Jennifer Zonderman

SVP, Global Marketing & US Commercialization

Jennifer Zonderman joined the US team in May 2019 and is now Senior Vice President Global Marketing & US Commercialization. Jennifer excels at leading sales organizations through change such as growth, new markets, product launches and team integrations. Focusing on process and system improvements and developing methods and teams to consistently achieve revenue goals is the key to her success. Jennifer’s sales career has spanned both medical and high tech; she has a Master’s Certificate from Wayne State and a Bachelor of Science from Alma College.

Ursula Klause, PhD

VP Research and Development

Ursula was appointed Vice President of Research and Development in December 2020. In this function, she leads a team of highly qualified and motivated scientists who are passionate about providing superior products to improve patients’ lives. She has a strong scientific background with more than 15 years in assay development and validation, system integration, biomarker discovery, and new technology assessments. Most recently, she served as a Senior Scientific Affairs Manager at Roche Diagnostics, where she managed and led industry-supported and industry-sponsored studies and served as point-of-contact for all customer off-label questions in regard to assays quality, standardization, and clinical utility. Ursula has a Master’s degree in Nutritional Sciences from the University of Bonn (Germany), and a PhD in Molecular Biology from the University of Cologne (Germany).

Asger Dahlgaard

VP Quality Assurance and Regulatory Affairs

Asger was appointed Vice President of Quality Assurance and Regulatory Affairs at BioPorto in October 2021. With more than 20 years in the medical industry and a key focus on quality management. Asger provides a proven track record in the management of global quality organizations, strategic thinking, and execution. While at Agilent Technologies, Asger managed a team of 45 to provide ongoing quality support including management reviews, and audits (FDA, notifying bodies, internal and vendor). His experience also includes managing and supporting major IT implementations and a new IVD-R system for Complaints, Vigilance, NCR, and Post Market Surveillance. Asger holds a Bachelor of Science in Engineering from the DTU-Technical University of Denmark.

Tabari Baker, PhD

VP Global Medical Affairs

Dr. Tabari Baker was appointed Vice President of Global Medical Affairs in February 2023. Dr. Baker most recently served as Director of Strategic Healthcare Partnerships at Roche Diagnostics, where he led cross-enterprise initiatives to communicate its diagnostic portfolio’s medical value throughout the patient journey. Also at Roche, Dr. Baker supported the launch of multiple companion diagnostic tests by providing clinical, scientific, and educational expertise as a Scientific Affairs Manager. Previously, Dr. Baker served in research and clinical liaison roles at Caris Life Sciences. Dr. Baker received his Ph.D. in Tumor Biology from Georgetown University. He earned an M.S. in Cancer Biology, Prevention, and Control from the University of the District of Columbia, and a B.S. in Chemistry from Morehouse College. 

Dr. Prasad Devarajan

Senior Medical Director

With over 40 years of medical experience, Dr. Prasad Devarajan, MD, FAAP, FASN, joined the BioPorto team as Senior Medical Director in July 2022. He is a world-renown pediatric nephrologist at Cincinnati Childrens Hospital Medical Center in Ohio, where he is the Director of the Nephrology and Hypertension Division, Medical Director of the Stone Center, and Professor at the UC Department of Pediatrics. In addition, Dr. Devarajan is on the editorial and review boards of more than 20 journals and multiple US National Institutes of Health (NIH) study sections. He has authored more than 320 peer-reviewed journal articles, and his work has been continuously funded by NIH and several other foundations for over 30 years. He graduated from Lokmanya Tilak Municipal Medical College medical school.